Major Depression Disorder Clinical Trial
Official title:
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder: a Multicentre, Open-label, Parallel-group, Randomised Controlled Trial
The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of major depression disorder compared to venlafaxine hydrochloride sustained-release tablets, to provide evidence-based basis for clinical rational drug use.
The study included 80 patients with major depression disorder (aged 18 to 65 years) who meet the diagnostic criteria for depression in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Eligible patients were randomly assigned (1:1) to 8-week treatment with toludesvenlafaxine hydrochloride sustained-release tablets (n=40) or venlafaxine hydrochloride sustained-release tablets (n=40), followed up at period of enrollment as baseline and at the end of 2th, 4th and 8th weeks. Adverse events were recorded. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02773108 -
Somatic Comorbidities in Psychiatric Patients
|
||
| Completed |
NCT02400346 -
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
|
Phase 3 | |
| Recruiting |
NCT05597566 -
Predictive Effect of Neuroinflammatory Factors of the MECT in Treatment of Senile Depression
|
||
| Recruiting |
NCT02273154 -
Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder
|
Phase 4 |